Evidence map›Paper›PMID 40420664›Full record

ArticleJournal of diabetes investigation2025

PIK3R1 mutations in individuals with insulin resistance or growth retardation: Case series and in silico functional analysis.

Tomofumi Takayoshi, Yushi Hirota, Aki Sugano, Kenji Sugawara, Takehito Takeuchi, Mika Ohta, Kai Yoshimura, Seiji Nishikage, Akane Yamamoto, Yu Mimura and 6 more

Abstract readCase Reports
In one paragraph

Article in Journal of diabetes investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Tomofumi TakayoshiDivision of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
Yushi HirotaDivision of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.ORCID https://orcid.org/0000-0002-3035-4155
Aki SuganoLaboratory of Pharma-Medical Informatics and AI, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan.
Kenji SugawaraDivision of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.ORCID https://orcid.org/0000-0002-6549-7885
Takehito TakeuchiDivision of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
Mika OhtaDepartment of Medical Systems, Kobe University Graduate School of Medicine, Kobe, Japan.
Kai YoshimuraDivision of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.ORCID https://orcid.org/0009-0002-6144-1320
Seiji NishikageDivision of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
Akane YamamotoDivision of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
Yu MimuraDivision of Pediatrics, Toyosato Hospital, Toyosato, Shiga, Japan.
Shinji HiguchiDivision of Pediatric Endocrinology, Metabolism and Nephrology, Children's Medical Center, Osaka City General Hospital, Osaka, Japan.
Jun MoriDivision of Pediatric Endocrinology, Metabolism and Nephrology, Children's Medical Center, Osaka City General Hospital, Osaka, Japan.
Rie KawakitaDivision of Pediatric Endocrinology, Metabolism and Nephrology, Children's Medical Center, Osaka City General Hospital, Osaka, Japan.
Tohru YorifujiDivision of Pediatric Endocrinology, Metabolism and Nephrology, Children's Medical Center, Osaka City General Hospital, Osaka, Japan.ORCID https://orcid.org/0000-0002-8945-4775
Yutaka TakaokaDivision of Bioinformatics, Center for Advanced Antibody Drug Development, University of Toyama, Toyama, Japan.
Wataru OgawaDivision of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.ORCID https://orcid.org/0000-0002-0432-4366

Funding

JSPS KAKENHI 19K08981Research on Standardizing the Treatment of Rare Diseases Causing Diabetes Through the Creation of a Registry of the Japan Diabetes SocietyResearch Program for Intractable Disease of the Ministry of Health, Labor and Welfare of Japan 24FC1015
6 · The paper itself

Abstract

AIMS/

introductionPhosphatidylinositol 3-kinase (PI3K) plays a key role in insulin signaling, and mutations in PIK3R1, which encodes a regulatory subunit (p85α) of this enzyme, are responsible for SHORT syndrome, which is associated with insulin-resistant diabetes. We here describe four Japanese individuals from three families with SHORT syndrome who harbor either a common or a previously unknown mutation in PIK3R1 as well as provide an in silico functional analysis of the mutant proteins. MATERIALS AND

methodsGene sequencing was performed to identify PIK3R1 mutations. 3D structural analysis of wild-type and mutant p85α proteins was performed by homology modeling, and structural optimization and molecular dynamics simulations confirmed stable trajectories. Docking simulations of p85α with a phosphopeptide were also conducted.

resultsWe identified two families with a common mutation (c.1945C>T, p.R649W) and one family with a previously unidentified mutation (c.1957A>T, p.K653*) of PIK3R1. In silico modeling revealed that both mutations impaired binding of p85α to phosphopeptide, with K653* resulting in the loss of amino acids that contribute to such binding. Docking simulations showed a significant loss of docking energy for the R649W mutant compared with the wild-type protein (P = 0.00329).

conclusionsThe four cases of SHORT syndrome were associated with early-onset diabetes and intrauterine growth retardation, with the identified mutations likely disrupting the binding of p85α to phosphopeptide and thereby impairing insulin signaling. One case uniquely manifested diabetes without insulin resistance, emphasizing the need for further study of the clinical variability of SHORT syndrome, especially with regard to its associated diabetes.

Indexed as

Class Ia Phosphatidylinositol 3-KinaseGrowth DisordersInsulin ResistanceLimb Deformities, CongenitalMutationPhosphatidylinositol 3-KinasesComputer SimulationHumansHypercalcemiaMetabolic DiseasesMolecular Docking SimulationNephrocalcinosisPedigreeClass Ia Phosphatidylinositol 3-KinasePhosphatidylinositol 3-KinasesPIK3R1 protein, humanIn silico analysisInsulin resistance syndromePIK3R1 mutation

Identifiers

PMID40420664
PMCPMC12315245

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.